Civitas Therapeutics, Inc. Company Profile
Civitas is a privately held pharmaceutical company focused on developing products with a clinically proven dry powder pulmonary delivery platform. The proprietary dry powder and device combination is unique in its ability to deliver a large, precise dose independent of inspiratory flow rate from a simple, passive device. The technology has successfully delivered more than one million doses to patients and the manufacturing technology has been scaled to accommodate a significant commercial launch. The lead program is for Parkinsonâs disease with clinical proof of concept anticipated to be complete in 2012. Additional programs encompass pulmonary disease, allergy, and pain.
News Articles
Alkermes Spinout, Civitas, Nabs Second Grant From Fox Foundation
Civitas was spun out of Alkermes (NASDAQ: ALKS) two years ago based on technology that can deliver a precise, high dose of a drug through an inhaler. With a new round of cash from the Michael J. Fox F...
Alkermes spin out Civitas reports CVT-301 data
Civitas Therapeutics Inc. (Chelsea, Mass.) said a single 50 mg dose of CVT-301 as an adjunct to standard oral medication met the primary endpoint of improving motor function vs. placebo in the Phase I...
Civitas Therapeutics to Present at Jefferies 2013 Global Healthcare Conference
Civitas Therapeutics, Inc., a biopharmaceutical company with a lead program in Parkinson’s disease that leverages the ARCUS(TM) respiratory delivery platform, today announced th...
Civitas Therapeutics Appoints Bryan E. Stuart Chief Business Officer
Civitas Therapeutics, a privately-held pharmaceutical company developing inhaled therapeutics with the clinically-proven ARCUS(TM) dry powder platform, today announced that...
Civitas launches Phase 2a Clinical Study of CVT-301
Civitas Therapeutics that uses the ARCUS respiratory delivery platform in developing transformative therapeutics, has announced the start of Phase 2a clinical trial in Parkinson's patients evaluating...
Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease
Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, today announced positive topline results from...
Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference
Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today that the Company will make its...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Civitas is a privately held pharmaceutical company focused on developing products with a clinically proven dry powder pulmonary delivery platform. The proprietary dry powder and d...
More Information about "Civitas Therapeutics, Inc." on BioPortfolio
We have published hundreds of Civitas Therapeutics, Inc. news stories on BioPortfolio along with dozens of Civitas Therapeutics, Inc. Clinical Trials and PubMed Articles about Civitas Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Civitas Therapeutics, Inc. Companies in our database. You can also find out about relevant Civitas Therapeutics, Inc. Drugs and Medications on this site too.
